A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...

Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...

The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity will soon unveil a new ...

Maryland’s Medicaid program now offers partial coverage of popular obesity drugs, with the state spending more than $68 ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to ...

Study authors point to semaglutide medication and “behavior changes” as possible reasons for the drop in obesity rates in the ...

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.

We have been giving a lot of attention to RFK Jr recently, with good reason. He is poised to be put in charge of the federal ...